Allergan (AGN) - Get Report has been tracing out a healthy pullback for the last five weeks. By Wednesday of last week, the stock had fallen more than 7% from its February high as it tested the 50-day moving average for the first time this year. AGN has rebounded nicely since then and may be in the early stages of a fresh rally leg.

Allergan is a holding in Jim Cramer'sAction Alerts PLUS Charitable Trust Portfolio. Want to be alerted before Cramer buys or sells AGN? Learn more now.

Allergan began the second leg of its powerful post-election rally with a breakout move on Feb. 1. The stock gained more than 4.75% that day and finished the session above its 200-day moving average for the first time since January 2016. AGN extended the breakout another $20 higher before running out of steam on Feb. 9. A week later, as the stock entered extremely overbought territory, it was clear a consolidation would be needed before further upside. This healthy process drove shares back down to a solid support zone.

It now appears AGN has put in a near-term low after testing the top band of a key support zone between $234.00 and $230.00. This important area is marked by the 50-day moving average near the upper band and the 200-day moving average near the lower band. Investors should take a more positive view of the stock as it continues to improve above this zone. 

TST Recommends

Image placeholder title

View Chart In A New Window